DAY ONE BIOPHARMACEUTICALS INC. - COMMON STOCK

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

06 май 2025 13:01:00 Источник Nasdaq GlobeNewswire

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

22 апр 2025 05:29:59 Источник Nasdaq GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

25 фев 2025 13:05:00 Источник Nasdaq GlobeNewswire

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

11 фев 2025 05:30:00 Источник Nasdaq GlobeNewswire

Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

13 янв 2025 05:00:01 Источник Nasdaq GlobeNewswire

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17 дек 2024 05:30:34 Источник Nasdaq GlobeNewswire

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

20 ноя 2024 13:30:00 Источник Nasdaq GlobeNewswire

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

18 ноя 2024 05:30:00 Источник Nasdaq GlobeNewswire

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

30 окт 2024 13:01:00 Источник Nasdaq GlobeNewswire

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

16 окт 2024 05:30:00 Источник Nasdaq GlobeNewswire

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

30 июл 2024 04:30:00 Источник Nasdaq GlobeNewswire

Day One Announces Oversubscribed $175.0 Million Private Placement

30 июл 2024 04:00:00 Источник Nasdaq GlobeNewswire

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

18 июн 2024 05:30:00 Источник Nasdaq GlobeNewswire

Day One Announces Sale of Priority Review Voucher for $108 Million

30 май 2024 05:30:00 Источник Nasdaq GlobeNewswire

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

06 май 2024 13:30:00 Источник Nasdaq GlobeNewswire

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

23 апр 2024 12:56:39 Источник Nasdaq GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

26 фев 2024 13:30:00 Источник Nasdaq GlobeNewswire

Day One Announces Two New Appointments to Board of Directors

17 янв 2024 05:00:00 Источник Nasdaq GlobeNewswire

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

19 дек 2023 05:00:00 Источник Nasdaq GlobeNewswire

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

17 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire